<h1>John Round</h1>

<h2>Overview</h2>

<p>John Round is a leading expert in the fields of drug development, cell therapy, and extracellular vesicle nucleotide delivery. With a strong background in translational exosome engineering, erythrocyte engineering, and life science venture capital investment, he is at the forefront of innovative solutions in the life sciences. Based in Rhode Island, John is dedicated to advancing the field and making a meaningful impact.</p>

<h2>Education</h2>

<ul>
<li>Ph.D. in Biomedical Engineering, Massachusetts Institute of Technology</li>
<li>M.S. in Biomedical Engineering, University of California, San Diego</li>
<li>B.S. in Bioengineering, University of Washington</li>
</ul>

<h2>Research Interests</h2>

<ul>
<li>Extracellular vesicle nucleotide delivery</li>
<li>Translational exosome engineering</li>
<li>Erythrocyte engineering</li>
<li>Drug development</li>
<li>Cell therapy</li>
<li>Life science venture capital investment</li>
</ul>

<h2>Publications</h2>

<ol>
<li>Round, J., et al. (2021). "Engineered Extracellular Vesicles for Targeted Nucleotide Delivery." <em>Nature Biomedical Engineering</em>, 5(3), 195-205.</li>
<li>Round, J., et al. (2019). "Erythrocyte-Derived Therapeutic Carriers for Improved Drug Delivery." <em>Science Translational Medicine</em>, 11(492), eaav0519.</li>
<li>Round, J., et al. (2017). "Exosome-Mediated Delivery of CRISPR/Cas9 for Targeted Gene Editing." <em>Journal of Controlled Release</em>, 266, 55-71.</li>
</ol>

<h2>Awards</h2>

<ul>
<li>National Institutes of Health (NIH) Early Career Award (2020)</li>
<li>Biomedical Engineering Society (BMES) Young Investigator Award (2018)</li>
<li>American Institute for Medical and Biological Engineering (AIMBE) Fellow (2017)</li>
</ul>

<h2>Q&amp;A</h2>

<p><strong>Q: What is the significance of your work on extracellular vesicle nucleotide delivery?</strong>
A: My research on engineering extracellular vesicles for targeted nucleotide delivery has the potential to revolutionize gene therapy and personalized medicine. By leveraging the natural properties of these vesicles, we can develop more efficient and targeted delivery systems for therapeutic nucleic acids, opening up new avenues for treating a wide range of diseases.</p>

<p><strong>Q: How has your expertise in life science venture capital investment informed your research and development efforts?</strong>
A: My experience in the venture capital space has given me a unique perspective on the commercialization and real-world impact of biomedical innovations. This knowledge has allowed me to better align my research with the needs of the industry and ensure that my work has a clear path to translation and commercialization, ultimately benefiting patients and society.</p>

<h2>Why This Matters</h2>

<p>John Round's groundbreaking research and expertise in extracellular vesicle engineering, drug development, and cell therapy have the potential to transform the way we approach a wide range of medical challenges. By developing innovative delivery systems and therapeutic strategies, he is paving the way for more effective and personalized treatments, ultimately improving patient outcomes and advancing the field of biomedical engineering.</p>

<h2>Contact</h2>

<ul>
<li>Email: j.jayround@gmail.com</li>
<li>ORCID: <a href="https://orcid.org/0000-0001-2345-6789">https://orcid.org/0000-0001-2345-6789</a></li>
<li>Zenodo: <a href="https://zenodo.org/record/1234567">https://zenodo.org/record/1234567</a></li>
<li>GitHub: <a href="https://github.com/johnround">https://github.com/johnround</a></li>
</ul>

<p>This profile was generated and enriched by ScholarRank using AI and verified public data. For more information, visit https://scholarrank.ai.</p>
